And the first GLP-1 agonist for obesity/weight loss was approved a full decade ago
Due to widespread knowledge of their weight loss properties, Ozempic and other GLP-1 agonists are increasingly being prescribed to people who use them for weight loss rather than treating type 2 diabetes (Cohen, 2024)
Further recent international guidelines advocate for a structured, tiered approach to managing DKD, emphasising individualised, multifactorial risk reduction
No structured workout required
All reactions were carried out in technical duplicates to ensure reproducibility
[1] A similar medication, tirzepatide, is available as Mounjaro, approved for treating type 2 diabetes, and Zepbound, approved for weight management